Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and more than 100 projects in the pipeline.

In March 2009, Genentech became a wholly owned member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.

Press releases and filings related to the Roche merger.

A Unique History Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a fateful meeting in 1976, the two decided to start the first biotechnology company, Genentech.

Awards & Recognition Genentech regularly receives awards and recognition for its overall performance as a company, its management, its workplace culture, its contributions to the community and its patient advocacy.